Page last updated: 2024-12-09

(2-methylanilino)thiourea

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

(2-Methylanilino)thiourea is an organic compound with the chemical formula C8H10N2S. It is a white to yellowish solid that is soluble in water.

**Structure and Properties:**

* **Structure:** It consists of a thiourea moiety (NH2-CS-NH2) with a 2-methylanilino group (C6H4(CH3)NH-) attached to one of the nitrogen atoms.
* **Properties:**
* Molecular weight: 182.25 g/mol
* Melting point: 108-110 °C
* Boiling point: Not available

**Importance in Research:**

(2-Methylanilino)thiourea is a versatile compound with potential applications in various research areas, including:

* **Drug Discovery:**
* **Antimicrobial Activity:** It has shown significant antimicrobial activity against a range of bacteria, including Staphylococcus aureus and Escherichia coli. Its mechanism of action is thought to involve inhibition of bacterial growth by interfering with the synthesis of essential cellular components.
* **Anticancer Activity:** Some studies suggest that it possesses anticancer activity, particularly against breast cancer cells. Its potential as a cancer therapeutic agent is being investigated.
* **Materials Science:**
* **Polymer Chemistry:** It can be used as a monomer for the synthesis of novel polymers with potential applications in various fields, such as electronics and biomaterials.
* **Metal Coordination Chemistry:** It acts as a chelating agent, forming complexes with metal ions. This property makes it useful in the development of metal-organic frameworks (MOFs) and other coordination complexes with potential applications in catalysis, sensing, and drug delivery.
* **Analytical Chemistry:**
* **Spectrophotometry:** It can be used as a reagent in spectrophotometric methods for the determination of various analytes, including metal ions and organic compounds.

**Current Research and Future Prospects:**

Ongoing research focuses on exploring the potential applications of (2-methylanilino)thiourea in various fields, including:

* **Optimizing its antimicrobial activity and developing novel antimicrobial agents.**
* **Investigating its anticancer properties and developing targeted therapies for cancer treatment.**
* **Synthesizing new polymers and MOFs with unique properties and potential applications.**
* **Developing new analytical methods for the detection and quantification of analytes.**

The versatility and potential of (2-methylanilino)thiourea make it an exciting area of research with the potential to contribute to advancements in various disciplines.

**Note:** It is important to note that while (2-methylanilino)thiourea shows promise in research, it is still in the early stages of development. Further research is needed to understand its full potential and safety profile before it can be used in clinical applications.

Cross-References

ID SourceID
PubMed CID1490896
CHEMBL ID1353091
CHEBI ID108936
SCHEMBL ID11750548

Synonyms (24)

Synonym
nsc 97210
brn 0880437
smr000336171
MLS000764026
2-(2-methylphenyl)-1-hydrazinecarbothioamide
STK039155
2-(2-methylphenyl)hydrazinecarbothioamide
CHEBI:108936
(2-methylanilino)thiourea
AKOS005083341
A833206
1-[(2-methylphenyl)amino]thiourea
NCGC00246535-01
HMS2711H10
3-12-00-01882 (beilstein handbook reference)
1P-072
[(2-methylphenyl)amino]thiourea
20174-30-5
1-(o-tolyl)-3-thiosemicarbazide
YRABENKRWXQGMK-UHFFFAOYSA-N
CHEMBL1353091
SCHEMBL11750548
Q27187908
tolylthiosemicarbazid
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
phenylhydrazinesAny member of the class of hydrazines carrying a phenyl substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (13)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency1.12200.044717.8581100.0000AID485294
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency15.81140.140911.194039.8107AID2451
phosphopantetheinyl transferaseBacillus subtilisPotency50.11870.141337.9142100.0000AID1490
GLS proteinHomo sapiens (human)Potency11.22020.35487.935539.8107AID624170
TDP1 proteinHomo sapiens (human)Potency21.85280.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency17.78280.180013.557439.8107AID1460
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency22.38720.011212.4002100.0000AID1030
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency11.22020.035520.977089.1251AID504332
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency11.22020.036619.637650.1187AID2100
DNA polymerase betaHomo sapiens (human)Potency63.09570.022421.010289.1251AID485314
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency89.12510.050127.073689.1251AID588590
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency10.66550.00798.23321,122.0200AID2546; AID2551
VprHuman immunodeficiency virus 1Potency35.48131.584919.626463.0957AID651644
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]